Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Recruiting now

Conditions studied: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8

In brief

This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced disease have been found to have abnormalities in DNA repair. The purpose of this research is to study the role of a DNA repair pathway in prostate cancer, specifically in response to administration of radium-223, an FDA-approved drug known to cause DNA damage to cancerous cells. Understanding how defects in the DNA repair pathway affects radium-223 treatment of prostate, may help doctors help plan effective treatment in future patients.

Key facts

Study ID

NCT04489719

Run by

University of Washington

People needed

48

Starts

2021-04-16

Expected to finish

2029-08-01

Last updated by the study team

2026-02-17

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patient must be >= 18 years of age
• Patient must have histopathologic diagnosis of prostate cancer
• Patient must have castration-resistant prostate cancer
• Patient must have radiographic evidence of bone metastasis
• Patients must be symptomatic from prostate cancer
• Patient must have plans to undergo treatment with radium-223
• Patient must have a PSA level >= 10 ng/mL
• Patient must have castrate testosterone levels demonstrated within the last 3 months prior to screening
• Patient must have anticipated survival > 3 months
• Patient must be willing and able to authorize consent
• Patient must be willing and able to comply with the protocol, including follow-up visits

You may not qualify if…

• Patient must not have visceral metastasis
• Patients on regimens of radium-223 in combination with other antineoplastic agents are excluded
• Bone-targeted only therapy (e.g. denosumab or zoledronic acid) will be allowed
• Patients who have received prior radium-223
• Patients who have received prior platinum containing chemotherapy
• Absolute neutrophil count (ANC) < 1.5 x 10\^9/L
• Hemoglobin (HB) < 9 g/dL
• Platelets (PLT) < 100 x 10\^9/L
• Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation

Where it is running

• Johns Hopkins University — Baltimore, Maryland, United States (enrolling)
• Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States (enrolling)
• University of Wisconsin-Madison — Madison, Wisconsin, United States (enrolling)
• Bozeman Health Deaconess Hospital — Bozeman, Montana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.